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Abstract:
Background:
There is evidence of hypnosis being effective in reducing both emotional distress, anxiety, and depression.
Hypnosis as a technique promotes enhanced mental mastery over the body. This may result  in hypnosis being particularly salient in treating
distress associated with somatic and psychological symptoms.
Objective:
This research aims at verifying the effectiveness of a group treatment, which provides for the use of hypnosis-related techniques in mixed-group
outpatients with anxiety or depression.
Methods:
Participants. 31 outpatients (average age= 49.005; DS =12.1) including 13 with mild-moderate depression (average age= 49.17; DS=12.20) and 18
with mild-moderate anxiety (average age=48.84; DS=13.02).
Procedure. The group treatment comprised 8 sessions, during which a hypnotic state was induced, aimed at generating a sensation of profound
wellbeing  in  the  participants.  They  could  share  their  experience  in  a  penultimate  group  session,  and  were  provided  with  individualised
recommendations on nutrition and lifestyle in the last individual session. Patients were prescribed to practice self-hypnosis every day at home with
the support of a CD-ROM.
Psychopathological symptomatology (SCL-90R), depression (BDI), and anxiety (STAI-Y1, SAS) were assessed at pre, post, and 3-month follow-
up.
Statistical analysis. Friedman, Kruskal-Wallis and Mann-Whitey tests were used. The Bonferroni’s correction was applied as needed. The effect
size (Cohen’s d) was also measured.
Results:
For the total sample, for all tests, significant differences were observed in the phases. The effect size was found to vary from “small” at pre to
”medium” at post. A “large” effect size was observed when comparing pre and follow-up phases. An overall reduction in the symptoms of distress
measured by the SCL-90 R – with the anxiety group showing better outcomes – alongside with an improvement in the symptoms of depression and
anxiety were observed in all participants.
Conclusion:
The  clinical  impact  appears  to  be  relevant,  as  shown  by  the  values  for  d.  The  treatment  is  cost-effective  for  highly  prevalent  disorders  in
outpatients. The outcomes of this study support the effectiveness of hypnotic group treatment.
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1. INTRODUCTION
Hypnosis is defined as “A state of consciousness involving
focused  attention  and  reduced  peripheral  awareness  charac-
terized by an enhanced capacity for response to sugges-tion.”
[1,  2].  Hypnosis  may  be  distinguished  from  other  states  of
consciousness  such  as  normal  waking  state,  sleep,  deep
relaxation  or  meditation  via  encephalogram  (EEG)  and
imaging methods [3]. Hypnosis has attracted growing interest
in  cognitive  neuroscience;  this  said  the  studies  of  the  neural
correlates  are  applying  brain-imaging  techniques,  which  can
provide refined analyses of both the location and time course of
brain activity involved in hypnotic experience [4, 5].
Hypnotic induction is a process to induce the state required
for  hypnosis  to  occur.  This  definition  does  not  however,
specify procedures or the context where these can be applied.
Thus, it may include procedures involving interaction between
a  therapist  and  a  patient,  self-hypnosis  procedures,  or  other
procedures that could be identified in the future thanks to the
advances in technology [1].
Hypnosis  may  have  diverse  applications  according  to  its
objectives. These include the following: medical hypnosis, e.g.
aimed  to  relieve  somatic  symptoms,  reducing  the  stress
experienced  as  a  result  from  medical  procedures,  and
improving physiological parameters; hypnotic communication,
with  suggestions  that  do  not  rely  on  trance;  hypnotherapy
aimed  at  generating  behavioural  changes  and  modifying
cognitive-affective  patterns,  restructuring  for  coping  with
emotionally  stressful  events,  and  for  the  reintegration  of
dissociate feelings [6, 3]. Medical hypnosis is characterized by
the application of hypnotic techniques, whether or not with the
use  of  induced  trance  states.  The  subsequent  use  of  guided
imagery,  widely  used  during  trance,  is  apt  to  re-establish
positive ways of perceiving the experience, as well as to reduce
automatic dysfunctional thinking loops [7].
Hypnosis may be used alone or integrated with other forms
of  psychotherapy  for  therapeutic  purposes.  In  this  respect,
hypnosis  has  been  integrated  with  some  evidence-base
approaches.  Such  an  example  is  the  integration  with  the
Cognitive-Behavioural  Therapy  (CBT).  A  number  of  mutual
features, such as the use of images and relaxation, as well as
the involvement of common cognitive processes, e.g. focused
thinking  and  expectations,  facilitate  integration.  As  an
example,  the  Systematic  Desensitization  (SD)  with  hypnosis
treatment included a hypnotic induction and suggestions that
involved coping imagery. The SD without hypnosis included
progressive relaxation instead of a hypnotic induction and did
not include the suggestions with coping imagery. As described
in  Forbes’  dissertation  [8],  it  has  been  observed  that  the
subjects  receiving  SD  with  hypnosis  experienced  greater
anxiety  reduction  than  the  subjects  receiving  SD  with
progressive  relaxation.  The  possible  addictive  effects  of
hypnotherapy  combined  with  CBT  have  been  discussed  by
Kirsch et al. [9], and Sadat Madani and Tavallaii Zavareh [10].
With respect to the treatment of depression, Alladin  has
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proposed  a  combination  of  Beck’s  cognitive  therapy  and
hypnosis [11, 12]. Cognitive Hypnotherapy has subsequently
been extended to patients with anxiety disorders [13].
Nevertheless, a study by Fuhr et al. [14] has contributed to
assess  the  importance  of  hypnotherapy  in  the  treatment  of
depression,  thus  verifying  the  hypothesis  that  the  average
improvement  in  the  Montgomery-Åsberg  Depression  Rating
Scale  score  will  not  be  inferior  in  hypnotherapy  when
compared  with  CBT  (non-inferiority  hypothesis).
It  should  also  be  noted  that  producing  a  hypnotic
phenomenon  does  not  necessarily  require  a  therapist  and  a
patient to interact: in fact, a hypnotic state can be induced alone
(self-hypnosis).  A  meta-analysis  of  hypnosis  in  medical
interventions  demonstrated  no  significant  differences  in
efficacy  between live  hypnosis  and suggestions  by  means  of
audio files [15]. Alladin and Alibhai [12], Yapko [16], Dobbin
et  al.  [17]  have  highlighted  that  self-hypnosis  allows  for
developing  antidepressive  pathways.
A study by Gruzelier [18] presents the positive effects of
self-hypnosis on the immune system, mood, and wellbeing in
general.  More  specifically,  hypnosis  was  found  capable  of
counteracting the effects of stress on the immune functions in a
group of medicine students, with reduction of viral infections
in wintertime.
Brugnoli et al. [19] point out that the reduction of pain and
anxiety  is  also  confirmed  when  individual  patients  practice
self-hypnosis at home.
Rutten  et  al.  [20]  have  observed  that  the  long-term
effectiveness of treatment with a hypnosis CD is non-inferior
to  that  of  hypnotherapy  by  therapists.  It,  therefore,  seems
recommendable  to  integrate  self-hypnosis  into  daily  routine
[21].  Besides  this,  it  seems  that  learning  techniques  of  self-
hypnosis  empower  patients  to  participate  in  their  own
treatment,  thus  also  promoting  patients’  independence.
Additionally, it is worth noting that hypnotherapy may be
performed one-on-one or in a group setting.
Téllez et al. [22] have verified the positive effects of group
hypnotherapy on anxiety, distress, optimism, and self-esteem in
breast cancer patients. Furthermore, Gregoire et al. [23] have
observed a decrease in anxiety, depression, and fatigue in the
hypnosis group in breast cancer patients.
Sahour et al. [24] concluded that group hypnotherapy was
effective in reducing anxiety and pain during labor. Beevi et al.
[25]  have  observed  a  reduction  of  stress,  anxiety,  and
depressive  symptoms  during  pregnancy  in  an  experimental
group.
In  a  multicentre  randomized  controlled  trial  in  patients
with irritable-bowel syndrome, Flik et al. [26] found that group
hypnotherapy was non-inferior to individual hypnotherapy.
Lastly, the results of a prospective randomized, controlled
study  with  patients  suffering  from  anxiety,  depression,  or
anxious-depressive  disorder  support  the  efficacy  of  group
hypnotherapy for mitigating anxiety and depression symptoms
[27].
Hypnotherapy  has  support  from  contemporary  clinical
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applications  and  researches  [28,  29].  Number  of  researches
support its  efficacy for a wide range of symptoms, including
the following: acute [30 - 32] and chronic pain [33], irritable-
bowel  syndrome  [34  -  36],  in  metastatic  breast  cancer  [37],
somatic  and  psychological  symptomatology  of  stress-related
disorders [38], depression [11, 39 - 42], anxiety [43, 44], and
for emotional distress reduction [21, 45].
As  regards  the  treatment  of  depression,  as  observed  by
Alladin [46], the use of hypnosis has been inhibited, based on
the  erroneous  belief  that  hypnosis  would  exacerbate  suicidal
behaviors.
It  is  currently  acknowledged  that  hypnosis  has  no
contraindications for hospitalised patients or outpatients with
depression,  especially  when  it  is  part  of  a  multimodal
therapeutic  approach  [16,  47,  48].  Another  reason  why
hypnosis is seldom used in the treatment of depression can be
attributed  to  the  absence  of  a  comprehensive  description  of
hypnotherapy in the literature [49].
Nonetheless, Yapko [16] has presented a series of clinical
considerations supporting the use of hypnosis for depression:
hypnosis  amplifies  the  subjective  experience,  helps  interrupt
symptomatic  patterns,  promotes  experiential  learning,
promotes the link and conceptualization of responses, provides
for  different  models  of  inner  reality,  and  helps  in  focused
attention.
As  regards  effectiveness  data,  the  positive  results  of
hypnosis  for  treating  depression  symptoms  observed  in  the
meta-analysis  by  Shih  et  al.  [40],  have  been  substantially
confirmed by the recent meta-analysis by Milling et al. [50].
As regards the treatment of anxious states, there is general
evidence  of  hypnotherapy  being  also  an  effective  treatment
method  for  anxiety  and  anxiety-related  disorders  [44,  51].
Hypnosis has been shown to be as equally helpful in reducing
anxiety as alprazolam 1mg [52] in reducing anxiety.
More  specifically,  several  studies  have  found  clinical
hypnosis  to  be  useful  in  the  treatment  of  anxiety  in  severe
chronic  diseases  [19,  53].  As  far  as  anxious  states  are
concerned,  Spiegel  [54]  argues  that  hypnosis  may  be  useful,
not only for its capacity of inducing relaxation, but also for its
typical dissociating element, which facilitates separation of the
psychological and somatic components of anxiety.
One  of  the  important  goals  for  utilizing  hypnosis  is  to
induce  relaxation.  The  relaxation  experience  is  particularly
meaningful  for  patients  with  anxiety,  or  with  comorbid
disorders (in both community and clinical samples, the average
comorbidity  rate  of  major  depressive  disorder  and  various
anxiety  disorders  is  more  than  50%,  and  the  lifetime  rate  is
76%)  [55].  This  said,  relaxation  can  also  benefit  patients
struggling  with  depression:  in  fact,  many  depressed  patients
display  a  comorbid  anxious  disorder  and  they  also  lack
confidence  in  their  abilities  to  effectively  handle  life
challenges. For these reasons, depressed patients often derive
significant benefit from learning to relax.
Distress related to psychological and somatic symptoms is
a hallmark feature for all the psychiatric disorders: particularly,
Anxiety  and  Mood  Disorders  share  overlapping  features
(restlessness,  irritability,  asthenia,  attention  deficit,  sleep
disorders, muscle tension, pain) [56, 57], and both anxiety and
depression involve a reciprocating cycle of mental and physical
distress.  Hypnosis  as  technique  involves  enhanced  mental
mastery over the body and this make the technique especially
salient to treatment.
A clinical improvement has been observed in a preliminary
study by Truzoli et al. [58] on patients diagnosed with anxiety
and depression. In this study, a reduction of the symptoms of
stress measured according to Symptom Checklist 90 R as well
as an improvement in the levels of depression and anxiety for
the overall sample had been observed.
In light of the abovementioned scientific evidence, a group
hypnotherapy protocol for patients diagnosed with depression
or  anxiety  has  been  drafted.  Halfway  through  the  process,
patients  were  prescribed  to  practice  self-hypnosis  with  the
support  of  a  CD-ROM,  with  the  purpose  of  reducing
psychological  and somatic stress and depressive and anxious
symptomatology. The aim of this work is therefore to evaluate
the  impact  of  a  group  hypnosis-based  treatment  on
psychological  and  somatic-related  distress,  as  well  as  on
depression and anxiety in a mixed-group of 31 outpatients with
anxiety or depression diagnosis. Besides, the two anxious and
depressed  subgroups  were  compared,  with  the  aim  of
investigating any potential differentiated effect on the levels of
distress,  depression,  and  anxiety.  When  present,  the
improvement  of  depression  and  anxiety  levels,  and  the
reduction in distress, were measured via the four scales referred
to under Materials.
2. MATERIALS AND METHODS
2.1. Participants
Thirty-one  outpatients  (mean  age  =  49.005;  DS  =  12.1)
including  13  with  mild-moderate  depression  (mean  age  =
49.17; DS = 12.20) and 18 with mild-moderate anxiety (mean
age = 48.84; DS = 13.02). Diagnosis: among the patients with
anxiety disorders, 4 have generalized anxiety disorder, 9 have
adjustment disorder with symptoms of anxiety, 5 have Anxiety
Disorder Not Otherwise Specified (ADNOS). Among patients
with  depressive  disorders,  5  patients  showed  anxious-
depressive  syndrome,  7  patients  showed  a  recurring  major
depressive  disorder,  and  1  patient  showed  a  mood-disorder
NOS.
In the overall  sample, the males were 6, and females 25.
The  depressed  subgroup  included  one  male  and  12  female
participants;  the  anxious  subgroup  included  5  males  and  14
females. These data are impacted by the frequency of access to
our  Centre  for  the  treatment  of  anxious  and  depression
disorders – it should be noted that it is predominantly accessed
by female patients. In any case, our data reflect what is known
on the epidemiology of depression and anxiety disorders, with
higher prevalence rates in females.
All  patients  had  received  at  least  two  cycles  of  drug
treatment with adequate duration and dosage for each cycle as
indicated  by  the  guidelines,  for  a  mean of  3  months  prior  to
their referral to the psychological outpatients Unit. All patients
had  partial  response  to  pharmacological  treatment.  The
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judgment  of  partial  responsiveness  was  based  on  previous
guidelines [59] and consistent with the guidelines of the I.K.
National Institute for Health Care Excellence [60, 61].
2.1.1. Inclusion Criteria
Age between 18 and 65; established diagnosis of Anxiety
or Depression; partial response to pharmacological treatment.
2.1.2. Exclusion Criteria
Axis II [62] comorbidities, drug addiction, schizophrenia,
and/or medical condition.
2.2. Materials
2.2.1. Symptom Checklist 90 R (SCL-90 R) [63]
A  90-item  self-report  instrument  evaluating  a  range  of
psychopathological  symptoms:  somatization,  obsessive-
compulsive,  interpersonal  sensitivity,  depression,  anxiety,
hostility, phobic anxiety, paranoid ideation, and psychoticism.
Somatization  subscale  reflects  distress  arising  from  bodily
perceptions.  Complaints  focused  on  cardiovascular,
gastrointestinal, respiratory, and other systems with autonomic
mediation  are  included.  Obsessive-compulsive  reflects
symptoms typical of obsessive-compulsive disorder, with the
focus on thoughts, impulses, and actions that are experienced
as  irresistible  by  the  individual.  Interpersonal  sensitivity
focuses on feelings of personal inadequacy and inferiority in
comparisons with others. In Depression subscale, most of the
typical  symptoms  of  depressive  syndromes  according  to
current  diagnostic  criteria  are  included.  Anxiety  subscale  is
composed  of  symptoms  that  are  associated  with  manifest
anxiety, as nervousness, tension, and trembling as well as some
somatic correlates of anxiety are included. In hostility subscale,
thoughts,  feelings,  or  actions  characteristic  of  the  negative
affective  state  of  anger,  and  qualities  such  as  irritability  and
resentment are included. In phobic anxiety subscale, the items
are  actually  all  manifestations  of  agoraphobia.  Paranoid
ideation  is  represented  as  a  disordered  mode  of  thinking;
hostility, suspiciousness, grandiosity, centrality, fear of loss of
autonomy  are  included.  Psychoticism  is  represented  as  a
continuous dimension of human experience. The items include
withdrawal,  isolation,  and  schizoid  lifestyle  as  well  as  first-
rank  schizophrenia  symptoms  such  as  hallucinations  and
thought disorders. The sum of the scores on the nine subscales
produces  the  Global  Severity  Index  (GSI)  for  overall
psychological distress with an internal reliability (Cronbach α)
of 0.97 [64]. Factor analytic studies of the Italian version have
suggested  that  this  instrument  is  optimal  as  a  measure  of
symptom  distress  [65].
2.2.2. Beck Depression Inventory (BDI) [66]
A  21-item  self-report  questionnaire  assesses  the  clinical
symptoms of depression over the past week. The score is a sum
of  the  positive  answers,  ranging  from  0  to  63,  and  it  is
suggested that  scores of  11 or  greater  reflect  the presence of
depression. The internal reliability (Cronbach's α of the scale is
0.92 [67], with concurrent validity ranging from 0.55 and 0.73
for non-psychiatric patients.
2.2.3. Self-rating Anxiety Scale (SAS) [68]
A 20 items self-report  scale  that  assesses  the  complaints
(primarily  somatic  symptoms)  associated  with  anxiety
symptoms. The respondent indicates how often he or she has
experienced each symptom on a 4-point Likert scale consisting
of  “none  or  a  little  of  the  time”  (coded  as  1),  “some  of  the
time” (coded as 2), “good part of the time” (coded as 3), and
“most  or  all  of  the  time”  (coded  as  4).  The  raw  total  score
range  is  0–80.  Zung  [68,  69]  proposed  mean  z-scores  for
diagnostic categories (Anxiety Disorders = 58.7; Depression =
50.7) and healthy controls (33.8). In a clinical sample the test-
retest reliability range between 0.81 and 0.84 over a period of 1
to 16 weeks [70].
2.2.4. State Trait Anxiety Inventory Y1 (STAI-S) [71]
A 10 item-questionnaire that assesses anxiety states (how
do respondents feel at the time). This self-report scale rates the
affective,  cognitive,  and  physiological  manifestations  of
anxiety. Scores for each question range from 1 = never, to 4 =
almost always, and the total score can range from 20 to 80. A
score of greater than 45 is recommended as showing signs of
anxiety.  The  internal  reliability  of  the  scale  is  0.93,  and  a
concurrent validity of 0.52 to 0.80 [71].
2.3. Procedure
All patients have signed a document for informed consent.
The treatment comprised 8 weekly group sessions for the
duration of 45 minutes; a last group session; and an individual
closing session (for a total of 10 sessions). The whole duration
of the treatment was two and a half months.
The  first  four  group  sessions  focused  on  the  progressive
induction of  a  hypnotic  trance,  aimed at  allowing patients  to
experience trance and deep relaxation.
The following four sessions provided for the application of
psychotherapeutic techniques during a state of deep relaxation
(achieved by means of trance induction). More specifically, a
“change  generator”  (visualizing  the  future)  was  used  in  the
fifth  session;  a  timeline  with  colours  individually  chosen  by
participants and aimed at therapeutic purposes was introduced
within the sixth session; advanced restructuring techniques for
anger and aggressiveness were implemented within the seventh
session; the anchoring of the trance state was carried out in the
eight session, with the purpose of replicating the trance state
itself.
Patients were taught how to practise self-hypnosis. Starting
from the fourth sessions, they were encouraged to practise self-
hypnosis at least once a day at home for 10 minutes, with the
support of an audio CD containing the induction of the trance
states reached during the first four sessions.
The  last  group  session  focuses  on  elaborating  the  group
experience, whereas the last individual session was committed
to  psychoeducation  in  the  fields  of  lifestyle  and  nutrition,
including  customised  recommendations.
The data have been collected at pre, post, and three-months
follow-up,  and analysed by collaborators  who have not  been
involved in the conduction of the therapeutic group.
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2.3.1. Statistical Analysis
Friedman test was used for checking the occurrence of any
difference between the four scales used (SCL-90 R, BDI, SAS,
and  STAY  1)  with  three  repeated  measures  (pre,  post  and
follow-up), for the overall sample. The effect size (Cohen’s d)
was also calculated. Mann-Whitney test was used for all four
scales (SCL-90 R, BDI, SAS, and STAY 1), for verifying any
difference  between  the  depression  and  anxiety  groups.  The
Bonferroni’s correction was applied as needed. Kruskal-Wallis
test was used for attesting any difference between SCL-R 90
subscales with three repeated measures (pre, post and follow-
up) between anxious and depressed subgroups. Therefore, also
having considered that, in the two subgroups with depression
and  anxiety,  the  mean  age  was  statistically  equal,  Spearman
correlation was used to assess the association of the age and the
outcome, as regards all the employed scales (SCL-90 R, BDI,
SAS, and STAY 1) at pre-, post- and follow-up for the overall
sample.  As  regards  the  results  broken  down  by  gender,  the
outcomes observed in the participants have not been subject to
comparison,  given  the  small  number  of  male  participants
available  to  make  a  meaningful  comparison.
3. RESULTS
Dropout rates equal to zero for all phases.
No correlation was observed between age and SCL-90 R,
BDI, SAS, and STAI 1 both at post- and follow up- (always: p
>  0.08).  This  being  said,  the  outcome  and  age  are  not
associated.
Primarily,  for  the  overall  sample,  we  checked  for  any
differences  between  the  four  scales  used  (SCL-90  R,  BDI,
SAS, and STAY 1) in the phases (pre, post and follow-up).
Table 1 shows means and standard deviations at pre, post
and  follow  up  treatment  for  all  the  scales  for  the  overall
sample;  Friedman  test,  and  Cohen’s  d  for  dependent  data.
As  regards  the  overall  sample,  significant  differences
among the phases were observed (with Bonferroni’s correction
p=0.017)  for  all  tests.  The  effect  size  varies  from  small  to
intermediate between pre and post,  but it  appears to be large
when comparing pre and follow up.
Subsequently, we compared two subgroups (depressed and
anxious) for each of the four scales used in the phases (pre-,
post-, and follow-up).
Table 2 shows means and standards deviations for the three
phases  for  all  the  scales  employed,  for  the  group  of  patients
diagnosed  with  depression  and  for  the  group  of  patients
diagnosed  with  anxiety.
We applied Bonferroni's adjustment, for lowering 0.05 to
0.017. Upon application of this correction and for all scales, no
significant difference was observed between the depression and
anxiety  groups  –  except  for  scale  SCL-90  R  at  follow  up
(Mann-Whitney test: z = 2.73, p = 0.006). The scale SCL-90 R,
as  referred  to  under  Materials,  includes  nine  subscales.  A
subsequent statistical analysis was carried out to assess which
subscales contributed to the differences observed at follow-up.
Furthermore, when looking at the differences among subscales
SCL-90 R (with Bonferroni’s correction = 0.0057) between the
depression  and  anxiety  groups,  significant  differences  were
observed for the following subscales: Interpersonal Sensitivity
(feelings  of  inadequacy  towards  others),  Depression,  and
Psychoticism  (subscale  with  indirect  indicators,  i.e.  “Never
feeling close to other people”; Table 3).
Table 3 shows means and standard deviations for the three
SCL-90  R  subscales  for  which  significant  differences  were
observed among phases,  between the  depression  and anxiety
groups.
Table 1. Means (standard deviations) for overall symptoms (SCL- 90 R), depression (BDI), and anxiety (SAS and STAI Y1)
for the overall sample pre, post and follow up treatment, as well as Friedman Test (p) and Cohen's d.
Scales Pre Post Follow up Friedman χ2(2) (p) d
Pre vs. Post
d
Pre vs. Follow
SCL-90 R 87.32(41.90) 57.87(31.80) 48.84(20.74) 11.68 (0.003) 0.79 1.15
BDI Dep. 16.74(9.58) 10.32(7.81) 7.81(5.44) 23.66(< 0.0001) 0.75 1.15
SAS Anx. 43.68(11.08) 38.87(9.19) 33.74(5.88) 17.15 (0.0002) 0.47 1.12
Stay 1 Anx. 49.71(12.75) 42.29(11.77) 35.03(5.50) 20.53 (< 0.0001) 0.6 1.48
Table 2. Means (standard deviations) for overall symptoms (SCL-90 R), depression (BDI), and anxiety (SAS and STAY 1) for
the anxious and depressed subgroups at pre, post and follow up treatment.
Scales Depression Anxiety
Pre Post Follow up Pre Post Follow up
SCL-90 R 95.54(46.49) 66.85(26.99) 60.61(19.95) 81.39(38.51) 51.39(34.13) 40.33(17.20)
BDI Dep. 19.54(9.50) 12.69(9.03) 10.77(6.15) 14.72(9.37) 8.61(6.54) 5.67(3.72)
SAS Anx. 47.23(12.73) 40.08(10.49) 34.92(5.09) 41.11(9.26) 38.00(8.33) 32.89(6.39)
Stay 1 Anx. 51.38(14.21) 46.38(11.40) 36.00(4.60) 48.50(11.85) 39.33(11.43) 34.33(6.11)
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Table 3. Means (standard deviations) for Interpersonal sensitivity, Depression, and Psychoticism subscales of SCL-R 90 for
pre, post and follow up treatment, as well as Kruskal-Wallis Test (p) between anxious and depressed subgroups.
Anxiety Depression
Sub scales Pre Post Follow up Pre Post Follow up Kruskal-W. χ2(1) (p)
Interp. Sens. 8.00(4.48) 5.00(4.47) 4.39(2.61) 9.46(7.24) 7.00(3.70) 7.00(3.44) 11.74(0.001)
Depression 18.22(9.55) 10.50(8.31) 7.28(3.88) 18.46(9.69) 12.23(7.01) 11.54(4.85) 10.62(0.001)
Psychot. 5.83(2.87) 2.67(2.72) 2.55(2.01) 7.46(6.23) 4.61(3.04) 4.77(2.01) 9.18(0.002)
4. DISCUSSION
A significant reduction of the distress symptoms measured
by SCL-90 R, alongside with an improvement in the anxiety
and depression symptoms were observed in all participants.
Patients diagnosed with anxiety seem to improve more at
follow  up  for  Interpersonal  Sensitivity,  Depression,  and
Psychoticism. This indicates an improvement in the feelings of
personal inadequacy and inferiority in comparison with others,
as  well  as  improved  mood,  and  improved  dysfunctional
thought  content.
The clinical significance of the intervention is sufficiently
good:  the  effect  size  shows  a  relatively  important  clinical
impact.
As regards the total sample, the treatment seems effective
for different diagnostic categories (depression and anxiety). It
can therefore, reasonably be assumed that the intervention acts
on  symptoms  that  are  common to  both  diagnostic  categories
[56] and it could, therefore, be argued that the intervention has
impacted  factors  that  are  common  to  the  two  subgroups  of
patients. It should be also noted that these are disorders that are
often in comorbid: in fact, the depression subgroup exceeds the
cut-off  values  for  anxiety  at  pre-test,  while  the  anxiety
subgroup  exceeds  the  cut-off  for  depression  at  pre-test.
As regards the anxiety subgroup, a greater improvement is
observed  on  three  SCL-90  R  subscales.  We  can,  therefore,
assume  that,  as  regards  anxious  patients,  acquiring  coping
skills also positively impacts those anxious states that may be
triggered  in  social  contexts.  The  acquisition  of  coping  skills
leads  to  an  improved  sense  of  social  adequacy,  decreases
depressive  symptoms  (when  these  are  not  primary)  resulting
from anxiety, and improves dysfunctional thought content (i.e.
“afflicting  thoughts  about  sex”’,  “the  thought  of  having  a
severe physical illness”, or “the idea of something being wrong
in one’s mind”), thus reducing negative worry and generating
reassurance. Practising these exercises for at least three months
seems to be the absolute minimum requirement for stabilizing
said  improvements.  The  provision  of  a  self-hypnosis’  CD,
aimed at promoting the compliance of the research referred to
herein, is a strength of this work.
Further studies could focus on the opportunity of providing
personalised  feedback  via  SMSs  to  support  compliance.  In
literature,  there  is  evidence  supporting  the  efficacy  of  this
strategy [72] in several fields, both medical and psychological,
but  the  data  on  treatments  based  on  hypnotherapy  are  not
sufficient.
CONCLUSION
To conclude, notwithstanding the limits shown below, the
outcome supports the effectiveness of hypnotic group treatment
in  a  clinical  setting  with  outpatients  representing  a  broad
portion of the persons who recourse to mental health services.
The  programme  was  successful  with  patients  who  had
previously  demonstrated  insufficient  change  in  their
symptomatology  using  pharmacological  interventions  is
encouraging.  Thus,  the  current  results  suggest  that  this
hypnotic  group  treatment  offers  a  simple  and  cost-effective
way to augment management for the most common psychiatric
disorders claimed in public health settings, as complementary
intervention  in  case  of  patients  less  responsive  to  the  drug
treatment.
STUDY LIMITATION
This work has some limitations, such as the control group
is missing.  This said,  the treatment has been carried out  in a
clinical  setting,  which  made it  difficult  to  create  a  group for
comparing  the  outcomes  of  the  treatment;  nevertheless,  an
index  to  evaluate  clinical  significance  has  been  calculated
(effect  size).  Furthermore,  the  subgroups’  data  shall  be
interpreted  with  caution,  given  their  small  sample  size.  The
actual  application  of  the  exercises  has  not  been  objectively
assessed during the three months following the treatment. It has
been only assessed based on the feedback collected in a follow-
up session. Future researches might help to draw a method to
collect  data  (i.e.  weekly  monitoring  sheets,  or  follow-up  by
phone).
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